nivolumab
bms
['nadim', 'nsclc', 'nivo', 'sclc']
#asco2022 nadim ll trial: resectabl stage lll nsclc, neoadjuvant
nivo + cht vs. cht pcr; 36.8% vs 6.9%, or:7.8 pd-l1 is predictive; pd-l1&gt;50% pcr:61% g3-4 ae; 25% vs 10% 
Medical Oncologist